Anteris Technologies advances PARADIGM trial and manufacturing scale-up in third quarter
Anteris Technologies (ASX:AVR, NASDAQ:AVR) advanced its PARADIGM Trial, expanding into new countries and gaining regulatory approvals. The company also increased manufacturing capacity. Q3 operating cash outflows were US$22.9 million, with R&D expenses at US$21.3 million.
How this was made

The 30-second read
Why it matters
The trial update reduces uncertainty around product approval and commercial timing, which can improve valuation.
Market read
First‑report of trial recruitment and manufacturing scale‑up provides new material information for investors.
What to watch
Potential regulatory delays in Europe and competition from established TAVR players.
Background
Anteris Technologies (ASX:AVR, NASDAQ:AVR) is developing the DurAVR transcatheter heart valve and runs the PARADIGM clinical trial across multiple countries.
Ticker impact
Anteris Technologies disclosed continued progress in its PARADIGM trial and expanded manufacturing capacity in Q3 2026.
potential upward pressure as the market prices in reduced regulatory and execution risk
First‑report of trial recruitment and capacity expansion for a listed biotech typically moves the stock positively.
Market effects
Positive signal for the transcatheter heart‑valve sector and related device manufacturers.
May boost investor interest in Australian and US biotech listings.
Limited to cardiovascular device market; no broad macro effect.
Counterpoint
Trial progress may not translate into commercial success; execution risk remains high.
Key entities
- companyAnteris Technologies
Developer of the DurAVR transcatheter heart valve.



